Literature DB >> 9811751

CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo.

R D Berkowitz1, S Alexander, C Bare, V Linquist-Stepps, M Bogan, M E Moreno, L Gibson, E D Wieder, J Kosek, C A Stoddart, J M McCune.   

Abstract

CCR5-utilizing (R5) and CXCR4-utilizing (X4) strains of human immunodeficiency virus type 1 (HIV-1) have been studied intensively in vitro, but the pathologic correlates of such differential tropism in vivo remain incompletely defined. In this study, X4 and R5 strains of HIV-1 were compared for tropism and pathogenesis in SCID-hu Thy/Liv mice, an in vivo model of human thymopoiesis. The X4 strain NL4-3 replicates quickly and extensively in thymocytes in the cortex and medulla, causing significant depletion. In contrast, the R5 strain Ba-L initially infects stromal cells including macrophages in the thymic medulla, without any obvious pathologic consequence. After a period of 3 to 4 weeks, Ba-L infection slowly spreads through the thymocyte populations, occasionally culminating in thymocyte depletion after week 6 of infection. During the entire time of infection, Ba-L did not mutate into variants capable of utilizing CXCR4. Therefore, X4 strains are highly cytopathic after infection of the human thymus. In contrast, infection with R5 strains of HIV-1 can result in a two-phase process in vivo, involving apparently nonpathogenic replication in medullary stromal cells followed by cytopathic replication in thymocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811751      PMCID: PMC110545     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

2.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.

Authors:  A McKnight; D Wilkinson; G Simmons; S Talbot; L Picard; M Ahuja; M Marsh; J A Hoxie; P R Clapham
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

3.  Localization of human immunodeficiency virus 1 RNA in thymic tissues from asymptomatic drug addicts.

Authors:  A P Burke; D Anderson; W Benson; R Turnicky; P Mannan; Y H Liang; J Smialek; R Virmani
Journal:  Arch Pathol Lab Med       Date:  1995-01       Impact factor: 5.534

4.  Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.

Authors:  L Rabin; M Hincenbergs; M B Moreno; S Warren; V Linquist; R Datema; B Charpiot; J Seifert; H Kaneshima; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population.

Authors:  M Cornelissen; G Mulder-Kampinga; J Veenstra; F Zorgdrager; C Kuiken; S Hartman; J Dekker; L van der Hoek; C Sol; R Coutinho
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission.

Authors:  N Ahmad; B M Baroudy; R C Baker; C Chappey
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

7.  HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo.

Authors:  L Su; H Kaneshima; M Bonyhadi; S Salimi; D Kraft; L Rabin; J M McCune
Journal:  Immunity       Date:  1995-01       Impact factor: 31.745

8.  Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.

Authors:  R I Connor; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression.

Authors:  D D Richman; S A Bozzette
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  42 in total

1.  R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.

Authors:  R D Berkowitz; A B van't Wout; N A Kootstra; M E Moreno; V D Linquist-Stepps; C Bare; C A Stoddart; H Schuitemaker; J M McCune
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 coreceptor preferences determine target T-cell depletion and cellular tropism in human lymphoid tissue.

Authors:  J C Grivel; M L Penn; D A Eckstein; B Schramm; R F Speck; N W Abbey; B Herndier; L Margolis; M A Goldsmith
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Authors:  C A Stoddart; M E Moreno; V D Linquist-Stepps; C Bare; M R Bogan; A Gobbi; R W Buckheit; J Bedard; R F Rando; J M McCune
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline.

Authors:  H Blaak; A B van't Wout; M Brouwer; B Hooibrink; E Hovenkamp; H Schuitemaker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

5.  Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication.

Authors:  D Camerini; H P Su; G Gamez-Torre; M L Johnson; J A Zack; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

6.  Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.

Authors:  Zhenya Ni; David A Knorr; Laura Bendzick; Jeremy Allred; Dan S Kaufman
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

7.  Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.

Authors:  Louis Alexander; Sharon Zhang; Brian McAuliffe; David Connors; Nannon Zhou; Tao Wang; Michele Agler; John Kadow; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

8.  Coxsackievirus B4 infection of human fetal thymus cells.

Authors:  Fabienne Brilot; Vincent Geenen; Didier Hober; Cheryl A Stoddart
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses.

Authors:  Yoshiaki Nishimura; Tatsuhiko Igarashi; Olivia K Donau; Alicia Buckler-White; Charles Buckler; Bernard A P Lafont; Robert M Goeken; Simoy Goldstein; Vanessa M Hirsch; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

10.  IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivo.

Authors:  Cheryl A Stoddart; Mary E Keir; Joseph M McCune
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.